Research on the effectiveness of Low-Dose Naltrexone (LDN) in fighting cancer – an evidence-based review
Low-dose naltrexone (LDN) – typically 1–5 mg daily, far below the 50 mg standard dose for opioid dependence – has attracted interest as a potential adjuvant in oncology. Over the last two decades researchers have proposed two main ways LDN might affect cancer: (1) modulation of the opioid growth factor (OGF) – OGF receptor (OGFr) axis to…
